Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 36,600 shares, an increase of 28.4% from the June 15th total of 28,500 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 4,530,000 shares, the days-to-cover ratio is currently 0.0 days.
Virpax Pharmaceuticals Trading Down 18.6 %
NASDAQ VRPX opened at $1.36 on Monday. Virpax Pharmaceuticals has a 12 month low of $0.46 and a 12 month high of $10.70. The company’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $2.59.
Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($2.75) EPS for the quarter.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Virpax Pharmaceuticals
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured Articles
- Five stocks we like better than Virpax Pharmaceuticals
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Top 3 Defense Stocks That Should Be on Your Radar
- Stock Average Calculator
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Most Volatile Stocks, What Investors Need to Know
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.